Market Summary
|
DJIA
| 10567.33
|  | +2.95
|
 |
|
S&P500
| 1145.61
| | +5.17
|
|
|
NASDAQ
| 2358.95
| | +18.27
|
|
ADD .PK for Pinksheets
ADD .OB for OTC
|
|
|
 |
WSNA Watch List
 |
Stock Watch List - Wednesday the 10th of March 2010 |
 |
|
 | Staar Surgical Co. STAA
STAAR Surgical Receives CE Mark Approval for KS-X Preloaded Hydrophobic Acrylic Lens Injector System ________ STAAR Surgical Company (Nasdaq: STAA), a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today announced that it has received CE Mark approval for its KS-X Preloaded Hydrophobic Acrylic Injector for use in minimally invasive cataract surgical procedures. The CE Mark allows STAAR Surgical to market this foldable intraocular (IOL) KS-X lens delivery system in the European Union as well as other countries that recognize the CE Mark. It also signifies that STAAR's preloaded acrylic lens delivery system complies with applicable safety and quality standards. |
 |
 | Generex Biotechnology Corp. GNBT
Generex Presented Positive Study Data At the American Diabetes Association Scientific Sessions ________ Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that data in respect of two of its products was presented at the American Diabetes Association's (ADA's) 69th Annual Scientific Sessions held in New Orleans June 5 - 9, 2009. |
|
 | VIVUS, Inc. VVUS
VIVUS' Qnexa Shows Significantly Improved Blood Sugar Control Through Weight Loss In Patients With Type 2 Diabetes ________ VIVUS, Inc. (Nasdaq: VVUS), a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health, today announced that data from a year-long phase 2 trial (DM-230) evaluating Qnexa(TM) in patients with type 2 diabetes are being highlighted in an oral podium presentation at the American Diabetes Association (ADA) 69th Scientific Sessions (abstract 361-OR). The study demonstrated that Qnexa, an investigational new drug, significantly reduced patients' hemoglobin A1c (HbA1c) -- a key indicator of blood sugar control -- and helped patients achieve and maintain significant weight loss. The study also showed that Qnexa had a positive impact on other risk factors associated with diseases prevalent in people living with diabetes. |
|
 | FuelCell Energy, Inc. FCEL
POSCO Power Orders 30.8 MW of FuelCell Energy Modules and Components With Estimated Value of $58 Million _______ FuelCell Energy, Inc. (Nasdaq:FCEL), a leading manufacturer of high efficiency ultra-clean power plants using renewable and other fuels for commercial, industrial, government, and utility customers, today announced that POSCO Power, South Korea's leading independent power producer, ordered 30.8 megawatts (MW) of FuelCell Energy Direct FuelCell(r) (DFC(r)) modules and components. The order represents an estimated sales value to the Company of $58 million and calls for delivery during 2010 and early 2011. |
|
 | MDRNA, Inc MRNA
MDRNA, Inc. Receives Full FDA Approval of Generic Calcitonin-Salmon Nasal Spray for Osteoporosis _______ MDRNA, Inc. (NASDAQ: MRNA) announced today that it has obtained full U.S. Food and Drug Administration (FDA) approval of its Abbreviated New Drug Application (ANDA) for generic calcitonin-salmon nasal spray for the treatment of osteoporosis and that Par Pharmaceutical Companies, Inc. (NYSE: PAR) has launched the product.
Calcitonin-salmon nasal spray, a legacy product developed by MDRNA in the early 2000s, is the generic equivalent of Miacalcin(R) nasal spray, marketed by Novartis Pharmaceuticals Corporation. U.S. sales of Miacalcin(R) were approximately $112 million in 2008, according to IMS Health data.
|
|
|
 |
|
 |
|
|
